Efficacy of Vitamin C Vaginal Tablets as Prophylaxis for Recurrent Bacterial Vaginosis: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial

Vladislav N. Krasnopolskya, Vera N. Prilepskayab, Franco Polattic, Nina V. Zarochentseva,a, Guldana R. Bayramoval, Maurizio Caserini,d, Renata Palmieri,d,e

Abstract

Background: The aetiology of bacterial vaginosis (BV) is still unclear but it is currently considered to be a synergistic polymicrobial syndrome. BV can often arise as a chronic or recurrent disease. The reason for such recurrences is not well elucidated. Previous studies have suggested that vaginal vitamin C may be a useful treatment in reducing recurrence rate, by increasing vaginal acidification and thereby making up for the decrease in hydrogen peroxide that results from a reduction in the number of lactobacilli present. Based on the above-mentioned consideration, a study was performed that aimed to evaluate the effect of vitamin C in the prophylaxis of BV relapses.

Methods: This was a randomised, double-blind, placebo-controlled, parallel-group clinical trial. One hundred and forty-two women, after having been cured from a recent episode of BV by either metronidazole or clindamycin, were randomised to receive vitamin C (74 patients) or placebo (68 patients) as prophylaxis for six monthly cycles, starting within 24 hours of the determination of ‘BV cure’. The patients applied one vaginal tablet once a day for 6 consecutive days per month after menses.

Results: The rate of BV recurrence during the first 3 months was considerably lower in the vitamin C group (6.8%) than in the placebo (14.7%) group. Considering a 6-month treatment period, the recurrence rate in the vitamin C group (16.2%) was significantly lower (P = 0.024) than in the placebo group (32.4%). Moreover, at the same time point, the survival analysis of Kaplan Meyer was significant in favour of the vitamin C group compared with the placebo group (P = 0.029).

Conclusions: The study showed that regular use of 250 mg ascorbic acid vaginal tablets on 6 days per month for 6 months after successful treatment of bacterial vaginosis halves the risk of recurrence from 32.4% to 16.2% (P = 0.024).

Keywords: Bacterial vaginosis; Bacterial vaginosis prophylaxis; Vitamin C vaginal tablets; Ascorbic acid vaginal tablets

Introduction

Bacterial vaginosis (BV) is a common condition that affects almost one-third of women of childbearing age (29%) [1]. In Caucasian women, the prevalence is 5% to 15%; in African and black American women, it is 45% to 55%; and in Asian women the prevalence is less well studied, but in general it is around 20% to 30% [2].

The aetiology of BV is still unclear but it is currently considered to be a synergistic polymicrobial syndrome, characterised by depletion of Lactobacillus spp and an intense increase (100- to 1,000-fold above normal levels) in vaginal anaerobic bacteria, including Gardnerella vaginalis, Prevotella spp, anaerobic gram-positive cocci, Mobiluncus spp, Mycoplasma hominis and Atopobium vaginalis [3, 4], leading to a replacement of lactobacilli and an increase in vaginal pH.

BV can often arise as a chronic or recurrent disease and the reason for recurrences is not well known. Based on fluorescence in situ hybridisation of vaginal biopsy specimens, Mendling et al [4] have demonstrated that BV is associated with the development of an adherent polymicrobial biofilm that is highly organised and contains abundant Gardnerella vaginalis on the vaginal epithelium. Bacterial biofilms have recently been associated with several recalcitrant infections (involving Escherichia coli, Helicobacter pylori and Pseudomonas aeruginosa) [5]. The biofilm enhances bacterial attachment to epithelial surfaces, allows bacteria to reach much higher concentrations than in luminal fluids, and prevents the
drugs from reaching the bacteria, which reside in the film in a quiescent, latent state [6]. This observation might provide an explanation of the high rates of BV relapses [7, 8]. The presence of *Atopobium vaginae* strictly associated with *Gardnerella vaginalis* in the persistent and adherent bacterial biofilm has been confirmed [4], and seems to be the main reason for the failure of BV treatment [9]. Although some authors suggest that *Atopobium vaginae* may play a role in lowering the vaginal pH level through lactic acid production [10], Marconi et al have found that *Atopobium vaginae* content strongly increases if the vaginal pH is 4.9 or higher [11]. Therefore, they suggest that strains of this bacterium may have different capacities of lactic acid production but not to a significant level to safeguard the vaginal microflora.

Vaginal vitamin C is available as silicon-coated tablets containing 250 mg ascorbic acid. This formulation is able to release the vitamin over hours, allowing a statistically significant vaginal pH-lowering effect [12]. The efficacy of vaginal vitamin C in relieving BV signs and symptoms has been confirmed in two studies by Petersen et al [13, 14]. Moreover, Abbaspour et al have showed that the efficacy of vaginal vitamin C in BV treatment is non-inferior to that of standard local metronidazole gel therapy [15].

The main goal of BV therapy and, in particular, of BV prevention is to keep the vaginal pH at 4.5 or lower, in order to prevent the overgrowth of pathogens until the normal lactobacilli are re-established and able to maintain the pH themselves [16]. Anaerobes grow poorly at pH 4.5 or lower; the optimum pH for *Prevotella* spp and *Gardnerella vaginalis* growth is 6 - 7. In vitro studies show that the concentrations of these bacteria increase with increasing pH, but both are susceptible to low pH. An ideal way to manage recurrent BV would be to maintain the vaginal pH at 4.5 with a prophylactic treatment that is able to control the overgrowth of bacteria. In this context, a viable therapeutic agent could be ascorbic acid, as it may able to help re-establish and maintain the vaginal ecosystem.

Based on the above-mentioned considerations, the present study aimed to evaluate the potential effect of vitamin C, well known to have a vaginal pH-lowering effect, in the prophylaxis of BV relapses in patients who have been cured from a BV episode.

### Materials and Methods

#### Ethics

The study was fully Good Clinical Practice (GCP) compliant and was reviewed and approved by all relevant Independent Ethics Committees. All patients provided written informed consent prior to entering the study.
### Design and treatments

This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group clinical trial. The patient population, recruited in nine European sites located in Italy, Germany, Russia, Ukraine, Portugal and the Netherlands, consisted of 142 out-patient women, aged between 18 and 50 years, with history of recurrent episodes of BV defined as at least two acute episodes in the last 12 months. The BV diagnosis was based on the contemporary presence of at least three out of four Amsel criteria [17]: vaginal discharge, pH of vaginal fluid > 4.5, amine (fishy) odour of vaginal discharge after addition of 10% KOH (whiff test) and the presence of clue cells (> 20%) on microscopic examination.

Patients with diagnosis of human immunodeficiency virus (HIV) infection, gonorrhoea, *Treponema pallidum*, *Herpes genitalis*, trichomoniasis and/or candidiasis, or concomitantly treated with immunosuppressant, antibiotics, *Lactobacillus* preparations, acidifying agents, disinfectants, or vaginal douching were excluded.

Eligible women, cured (confirmed by the absence of three out of four Amsel criteria [17]) from an episode of BV by a course of either metronidazole or clindamycin, were randomly (1:1) assigned to receive 250 mg ascorbic acid vaginal tablets or placebo as prophylaxis for six monthly cycles, starting within 24 hours from the determination of ‘BV cure’. The patients applied one vaginal tablet once a day for 6 consecutive days per month after menses. The women were instructed to insert the tablets deep into the vagina at bedtime and were supplied with 250 mg ascorbic acid tablets or matching placebo.

The overall prophylaxis was set by six cycles of applications but, when the first BV relapse occurred (confirmed by the presence of three out of four Amsel criteria [17]), the patients were discontinued from the study.

### Assessments

Clinical visits were conducted at the end of each cycle, within 3 days of the end of the treatment, and 1 month after the end of the last cycle (final visit). The diagnosis of BV was documented by collecting two specimens of vaginal discharge: the first sample for microscopic examination (detection of clue cells) of the fresh smear and the second one for the whiff test. Moreover, BV signs and symptoms were recorded (itching, burning, dysuria, odour, erythema, oedema, and fissures) and scored by means of a four-point scale as follows: 0 = absent, 1 = mild, 2 = moderate and 3 = severe.

Vaginal pH measurements were performed by the patients themselves using a pH-measuring device, namely pHem-Alert® (Gynex Corporation, USA) during each cycle: before and 12 hours after the first application, 12 hours after the last application and during the application-free period on days 10 and 15.

The primary efficacy variable of the study was the time to the first BV relapse diagnosed according to Amsel criteria [17]. Secondary end-points were the evaluation of the pH-lowering effect of vitamin C, the evaluation of the frequency...
of BV sign and symptoms during the prophylaxis period, global assessment of the acceptability of the product by investigators and patients and the evaluation of the safety of vitamin C. The acceptability and tolerability of the product were evaluated by the patient and the investigator, respectively, according to the following five-point scale: 1 = very good, 2 = good, 3 = fair, 4 = poor and 5 = intolerance.

Statistical analysis

All randomised patients who fulfilled the inclusion/exclusion criteria and had received at least one dose of the study medication were included in the intention-to-treat (ITT) analysis. In case of premature discontinuation or missing data in completed patients, the last observation carried forward approach (LOCF) was used and the final available observation was considered as an end-point value. All enrolled patients were considered as the safety population. The sample size was determined based on the chi-square test and the power was 85% to detect an odds ratio (O.R.) of 0.26.

The randomisation list was computer-generated in blocks of four with treatments balanced (1:1) within blocks, by the Biometry Department of Medi Service s.r.l., Italy, using the SAS Package 8.2, validated routine from the Computerized System Validation Process. Variables of an ordinate classification and dichotomous type were tested by the chi-square test according to the Mantel-Hanszel extension. The pH-lowering effect and the vaginal signs and symptoms were analysed using the Mann-Whitney test for inter-treatment comparisons and the Friedman test for intra-treatment analysis. Investigators’ and subjects’ judgements on the acceptability of the product in the two treatment groups were compared using the Wilcoxon Rank Sum test.

All tests of hypotheses were performed using two-sided tests at a 5% significance level.

Results

Patient population

Overall, 142 women were randomised; 74 (52%) received
aspargin acid and the other 68 (48%) received placebo. The two groups were homogeneous for age, height and weight distribution. BV signs and symptoms (itching, burning, dysuria, odour, erythema, oedema and fissures) were fairly similar across treatment groups, as summarised in Table 1.

Proportion of patients free of BV relapses

The proportion of women having a BV recurrence in the ITT population during the first 3 months was 6.8% in the vitamin C group (5/74) and 14.7% (10/68) in the placebo group, but the difference between the groups was not statistically significant. After 6 months of treatment, the recurrence rate was 16.2% in the vitamin C group compared with 32.4% in the placebo group (Fig. 1), which was statistically significant (P = 0.024, chi-square test). The results were confirmed by the O.R. that represents the risk of a recurrent episode of BV in the group treated with vitamin C in comparison to the placebo group. After six cycles of prophylaxis, the O.R. was 0.405 (95% confidence interval (CI) = 0.182 - 0.901). The result was statistically significant since the 95% CI of the O.R. did not include the value ‘1’.

The Kaplan-Meier survival analysis (Fig. 2), probability of being free of BV relapse in the two groups during the period of prophylaxis, became statistically significant starting from the 5-month time point (P = 0.039 vitamin C vs. placebo, log-rank test); the significant difference was maintained and increased at the 6-month evaluation (end of treatment).

Table 2. Patients With at Least One AE (Safety Population)

| Adverse event             | Treatment group               |
|---------------------------|-------------------------------|
|                           | Vitamin C (n = 74) | Placebo (n = 68) |
| Burning, itching, skin irritation | 3 (4.0%) | 4 (5.9%) |
| Candidiasis               | 1 (1.4%) | 1 (1.5%) |
| Cystitis                  | -      | 1 (1.5%) |
| Nausea                    | -      | 1 (1.5%) |
| Bronchitis                | 1 (1.4%) | -      |
| Major depression          | -      | 1 (1.5%) |
| Flu                       | -      | 1 (1.5%) |
The results of the present study show that 250 mg ascorbic acid vaginal tablets taken 6 days per month safely halves the risk of BV recurrence from 32.4% to 16.2% during a 6-month prophylactic treatment. The O.R. confirms that subjects treated with placebo had a doubled risk of BV recurrence compared with the group of subjects treated with vitamin C. Considering the time to the first BV relapse, treatment of at least five cycles is necessary in order to reduce, at a significant level, the risk of BV recurrence. As this was a prophylaxis study, in women who at the screening visit were healthy and who terminated the study in case of relapse, a between-treatment difference in clinical parameters was not expected. At the same time, differences in pH were not expected but conversely, a reduction in pH was noted for 3-month and 6-month treatment.

In conclusion, regular use of silicon-coated vitamin C (250 mg) tablets, after the standard antibiotic treatment for BV, protects women by reducing the risk of recurrence probably by re-establishing the normal lactobacilli flora that is able to maintain vaginal pH.

**Acknowledgement**

The contribution of the following persons to the investigation is gratefully acknowledged: Medi Service S.r.l., Agrate Brianza, Milan, Italy; R. Fasani and G. Reggiardo.

**Conflicts of Interest and Source of Funding**

Vladislav N. Krasnopolsky, Vera N. Prilepskaya, Franco Polatti, Nina V. Zarochentseva, and Guldana R. Bayramova received honoraria from Polichem S.A. as study investigators. Maurizio Caserini and Renata Palmieri are employees of Polichem S.A.

Polichem S.A. sponsored all phases of the study and supplied the trial product.

**Abbreviations**

AE: adverse event; BV: bacterial vaginosis; EFS: event-free survival curve; GCP: good clinical practice; HIV: human immunodeficiency virus; ITT: intention-to-treat population; LOCF: last observation carried forward; O.R.: odds ratio; SD: standard deviation.

**References**

1. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007;109(1):114-120.
2. Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv. 2010;65(7):462-473.
3. Sobel JD. Bacterial vaginosis. Annu Rev Med. 2000;51:349-356.
4. Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP, Lochs H. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013-1023.
5. Tool GO, Kaplan HB, Kolter R. Biofilm formation as microbial development. Ann Rev Microbiol 2000; 54: 49-79.
6. Swidsinski A, Mendling W, Loening-Baucke V, Swidsinski S, Dorffel Y, Scholze J, Lochs H, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1-97.e6.
7. Hay P. Recurrent Bacterial Vaginosis. Curr Infect Dis Rep. 2000;2(6):506-512.
8. Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012;7(1):36-40.
9. Togni G, Battini V, Bulgheroni A, Maillard F, Caserini M, Mendling W. In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis? Antimicrob Agents Chemother. 2011;55(5):2490-2492.
10. Zhou X, Bent SJ, Schneider MG, Davis CC, Islam MR, Forney LJ. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology. 2004;150(Pt 8):2565-2573.
11. Marconi C, Cruciani F, Vitali B, Donders GG. Correlation of Atopobium vaginae Amount With Bacterial Vaginosis Markers. J Low Genit Tract Dis. 2012;16(2):127-132.
12. Polatti F, Rampino M, Magnani P, Mascarucci P. Vaginal pH-lowering effect of locally applied vitamin C in subjects with high vaginal pH. Gynecol Endocrinol. 2006;22(4):230-234.
13. Petersen EE, Magnani P. Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2004;117(1):70-75.
14. Petersen EE, Genet M, Caserini M, Palmieri R. Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial. Arzneimittelforschung. 2011;61(4):260-265.
15. Abbaspour Z, Goodarzy F, Abbaspour MR. Comparison effect of vitamin C vaginal tablet and metronidazole vaginal gel on treatment and relapse of bacterial vaginosis. Afr J Pharm Pharmacol 2010; 4: 484-489.
16. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8-11.
17. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22.
18. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478-1486.